Autograft cellular composition and outcome in NHL patients: results of the prospective multicenter GOA study

References

• Jantunen E, Varmavuo V, Juutilainen A, et al. Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Ann Hematol. 2012;91(7):1073–1079.
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Basak GW, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019;54(10):1575–1585.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood. 1998;91:3148–3155.
   PubMed Web of Science ®Google Scholar
• Allan DS, Keeney M, Howson-Jan K, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;29(12):967–972.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant. 2011;17(8):1146–1153.
   PubMed Web of Science ®Google Scholar
• Ungerstedt JS, Watz E, Uttervall K, et al. Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery. Med Oncol. 2012;29(3):2191–2199.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Jädersten M, Hellström A, et al. The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016. Exp Hematol Oncol. 2019;8(1):7.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2003;44(5):815–820.
   PubMed Web of Science ®Google Scholar
• Blystad AK, Delabie J, Kvaløy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol. 2004;125(5):605–612.
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(8):719–724.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma. Transfusion. 2009;49(9):1890–1900.
   PubMed Web of Science ®Google Scholar
• Jantunen E, Fruehauf S. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens. Bone Marrow Transplant. 2011;46(5):627–635.
   PubMed Web of Science ®Google Scholar
• Saraceni F, Shem-Tov N, Olivieri A, et al. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 2015;50(7):886–891.
   PubMed Web of Science ®Google Scholar
• Henon P, Sovalat H, Bourderont D, et al. Role of the CD34 + 38– cells in posttransplant hematopoietic recovery. Stem Cells. 2009;16(S2):113–122.
   Google Scholar
• Zubair AC, Kao G, Daley H, et al. CD34(+) CD38(–) and CD34(+) HLA-DR(–) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy. 2006;8(4):399–407.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33(3):291–298.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Pronschinske KB, Shyer JA, et al. T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res. 2016;4(1):61–71.
   PubMed Web of Science ®Google Scholar
• Porrata LF. Autologous graft-versus-tumor effect: reality or fiction? Adv Hematol. 2016;2016:1–8.
   Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma Trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175(3):410–418.
   PubMed Web of Science ®Google Scholar
• Gratama JW, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy. 2003;5(1):55–65.
   PubMed Web of Science ®Google Scholar
• Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells (‘super mobilizers’) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2007;40(5):437–441.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant. 2007;40(2):111–118.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance. Leuk Lymphoma. 2016;57(9):2025–2032.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98(3):579–585.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003;31(11):1009–1013.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14(7):807–816.
   PubMed Web of Science ®Google Scholar
• Schmidmaier R, Oversohl N, Schnabel B, et al. Helper T cells (CD3+/CD4+) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol. 2008;30:240–243.
   PubMedGoogle Scholar
• Herr MM, Torka P, Zhang Y, et al. Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. Bone Marrow Transplant. 2020;55(1):77–85.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Burgstaler EA, Winters JL, et al. Immunologic autograft engineering and survival in non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016;22(6):1017–1023.
   PubMed Web of Science ®Google Scholar
• Poznanski SM, Ashkar AA. What defines NK cell functional fate: phenotype or metabolism? Front Immunol. 2019;10:1414.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Autograft immune content and survival in non-Hodgkin’s lymphoma: a post hoc analysis. Leuk Res. 2019;81:1–9.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin’s lymphoma patients. Transfusion. 2014;54(5):1243–1250.
   PubMed Web of Science ®Google Scholar
• Sureda A, Chabannon C, Masszi T, et al. Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) registry on a cohort of lymphoma patients receiving plerixafor. Bone Marrow Transplant. 2020;55(3):613–622.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, Nademanee AP, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report. Biol Blood Marrow Transplant. 2018;24(6):1187–1195.
   PubMed Web of Science ®Google Scholar
• Valtola J, Varmavuo V, Ropponen A, et al. Effect of cryopreservation on the CD34+ cell counts and the T lymphocyte subsets in autologous blood grafts of patients with non-Hodgkin lymphoma and multiple myeloma. Bone Marrow Transplant. 2016;51:S134.
   PubMed Web of Science ®Google Scholar